The objective of the present study was to evaluate the performance of Abusign test slides in comparison with fluorescence polarization immunoassay (FPIA)-ADx and gas chromatography-mass spectrometry (GC-MS) confirmation with special emphasis on concentrations near the cutoff. Analysis was performed on 35 individual slide tests for cocaine (cutoff, 300 ng/mL), cannabinoids (cutoff, 100 ng/mL), and opiates (cutoff, 300 ng/mL); 104 tests for cannabinoids (cutoff, 50 ng/mL); and 34 panel slides (amphetamine cutoff 1000 ng/mL, cocaine cutoff 300 ng/mL, opiates cutoff 300 ng/mL, and cannabinoids cutoff 100 ng/mL). Urine samples that had a concentration measured with FPIA-ADx within • 25% of the Abusign cutoff were selected. Interand intra-individual agreement were assessed from the readings of the slides (positive or negative) by four persons at t = 3, 5, and 10 min after sample incubation. In addition, the sensitivity and specificity of the cannabinoids slide test (50 ng/mL) were compared with those of FPIA-ADx using GC-MS as the gold standard. There was a considerable variation in the reading of the slides between different persons. In addition, for the same observer the reading could depend upon the time of incubation. In comparison with FPIA-ADx, the Abusign test slides showed a high sensitivity (46% vs. 87%) and a low specificity (95% vs. 51%). We concluded that the Abusign slide test is unsuitable for situations in which a reliable test result is desired because of the low interindividual agreement, the dependecy of the test result upon time, and the low specificity. However, the test slides may be of value in toxicological screening.
Introduction
Several methods are available for screening urine for the presence of drugs of abuse, including fluorescence polarization immunoassay (FPIA), enzyme immunoassay (EMITTM), and *Current address: Ziekenhuisapotheek Apeldoom-Zutphen, Hospital Pharmacy, P.O. Box 9014, 7300 DS Apeldoorn, The Netherlands. *Author to whom correspondence should be addressed. 1The current name of Abusign TM iS Accusign TM. radioimrnunoassay (RIA). In addition, assays are available that allow visual and timely detection without the need for expensive equipment.
There is some literature available with respect to the performance of the On-Trak assay and the Triage panel (1) (2) (3) (4) , but there is no published information about the performance of the Abusign 1 slide tests. The Abusign slide test screens urine qualitatively for the presence of a specific drug of abuse according to the principle of a competitive immunoassay. After incubation, the 3-5 drops of urine move through the membrane in the slide and migrates to the reading and control zone. This reading zone contains an antibody-dye conjugate specific to the drugs being tested. If a drug is present in the urine, it will bind to the antibody-dye conjugate. If the amount of drug present in the urine is higher than the cutoff, all the antibody-dye conjugate will bind to the drug and be unable to bind to the immobilized drug in the reading zone; no pink line should appear. If there is no drug present in the urine, or if the concentration of the drug is below the cutoff concentration, some of the nonbound antibody-dye conjugate will bind to the immobilized drug in the reading zone; a pink line should become visible. A pink line should always appear in the control zone because it contains a special immobilized antibody. If no pink line appears in the control zone, the test result is invalid. According to the manufacturer, the result should be read between 3 and i0 min after the urine is added to the slide.
The objective of the present study was to evaluate the performance of Abusign test slides in comparison with FPIA-ADx and confirmation with gas chromatography-mass spectrometry (GC-MS) with special emphasis on concentrations near the cutoff.
Materials and Methods

Abusign slide tests
Five different Abusign slide tests were evaluated: cocaine (cutoff, 300-ng/mL benzoylecgonine), opiates (cutoff, 300-ng/mL morphine); cannabinoids (cutoff, 50-ng/mL 11-nor-Ag-THC-9-COOH); cannabinoids (cutoff, 100-ng/mL 11-nor-Ag-THC-9-COOH) and a test panel for four drugs. The latter tests simultaneously for the presence of amphetamine (cutoff, 1000-ng/mL amphetamine); opiates (cutoff, 300-ng/rnL morphine); cannabinoids (cutoff, 100-ng/rnL 11-nor-Ag-THC-9-COOH); and cocaine (cutoff, 300-ng/mL benzoylecgonine). Abusign slide tests were obtained from Uniprom Diagnostics (Kfimpen a/d I Jssel, The Netherlands).
Selection of the urine samples
Urine samples were obtained from several sources (e.g., prisons, detoxification centers) and selected after they had been analyzed in our laboratory with FPIA-ADx. For each type of slide test, approximately 35 samples were selected, except for the slide test for cannabinoids with a cutoff of 50 ng/mL. For this slide test, 104 samples were selected. In order to meet the objective of our study, the selection criterion for most of the samples was that the screening result obtained with FPIAADx was within the 75-125% range of the Abusign slide test cutoff value. In addition, a few samples with a concentration of the drug far above the cutoff were selected as positive controls. For the test panel, it was not possible to select samples with concentrations of all the drugs near the cutoff.
After the samples had been selected by screening with FPIAADx, they were stored and frozen at -40~ After enough samples had been collected, each sample was analyzed on the same day with an Abusign slide test and with FPIA-ADx and confirmed with GC-MS.
Assessment of performance of Abusign slide tests
The performance of the Abusign slide tests was assessed in several ways. First, the interindividual agreement was tested for the five different slide tests as well as the consistency of the observation made by the same person in time. The following procedure was used for this assessment. All the test slides were unpacked, numbered, and placed on a table. Four people (two men and two women) were instructed about how to read the slides, but they were not informed about the content of the samples. They were asked to read the slides 3, 5, and 10 rain after the urine was added to the slide and to write the result (positive or negative) on a standard form. They read the results independently of each other. Comments could be made on the readability of the slide test. Next, two randomly chosen samples were analyzed twice with the panel test and independently assessed by two observers. Finally, sensitivity and specificity of the test slide for cannabinoids (cutoff 50 ng/mL) were assessed using GC-MS as the gold standard, and they were compared with the sensitivity and specificity of FPIA-ADx. A sample was considered positive if the concentration measured with GC-MS was higher than 15 ng/mL in accordance with SAMSHA guidelines.
Reagents
The calibration and control standards used for FPIA-ADx were obtained from Abbott Diagnostics (Amstelveen, The Netherlands). The standards used in GC-MS analysis were 11-nor-Ag-THC-9-COOH and benzoylecgonine-tetrahydrate (Makor Chemicals, Jerusalem, Israel); methylenedioxyarnphetamine hydrochloride (MDA), methylenedioxyrnethyla phetamine hydrochloride (MDMA), and rnethylenedioxyethylamphetamine hydrochloride (MDEA) (Laboratory of the Ministry of Justice, Rijswijk, The Netherlands); amphetaminesulfate, methylamphetamine hydrochloride, morphine hydrochloride, and codeine-phosphate (OPG, Utrecht, The Netherlands); arnantadine hydrochloride and nalorphine hydrochloride (Bufa, Uitgeest, The Netherlands); and 11-nor-Ag-THC-9-COOH-d3 (Radian, Austin, TX). Bis(trimethylsilyl)trifluoracetamide (BSTFA) (Pierce, Oud-Beijerland, The Netherlands) was used as the derivatizing reagent for the confirmation of opiates, benzoylecgonine, and cannabinoids. Hepta-fluor-butyric-acid (Sigma Chemicals, Axel, Belgium) was used as the derivatizing reagent for the confirmation of amphetamines. 13-Glucuronidase (Sigma Chemicals) was used for enzymatic hydrolysis in opiates confirmation. All other chemicals and solid-phase extraction (SPE) cartridges (NARC-1 and NARC-2) were obtained from J.T. Baker (Deventer, The Netherlands).
FPIA screening
FPIA screening was performed on ADx (Abbott, Amstelveen, The Netherlands) using calibration and control standards from the manufacturer. It was used as a method to select the samples with a concentration close to the cutoff of the Abusign test slides.
Confirmation with GC-MS
All samples were confirmed using GC-MS according to standardized and validated procedures. A short description of the * Interindividual agreement: number of samples for which all four persons made an unequivocal observation at t = 5 rain.
Intra-individual agreement: number of samples for which that person made the same observation at t = 3, t = 5, and t = 10 rain. 
Results
In Table II , the agreement between different observers and the agreement per observer in time for the five different slide tests are presented. In the third column, the number of unequivocal observations at t = 5 rain, which reflected agreement between different observers, is shown. An observation was called unequivocal when all four people came to the same test result. The percentage of unequivocal observations for the cannabinoids tests and the panel test (all four tests together) was low. In the last four columns, the intra-individual agreement in observation with increasing observation time is shown. 1~vo randomly chosen samples (A and B) were analyzed twice with the Abusign panel test and judged twice by two volunteers in order to see if differences between the two analyses would appear (Table III) . Both volunteers had different observations for the second analysis of sample A (cannabinoids) when compared with the first analysis. This also occurred when volunteer 3 judged sample B the second time for the presence of cannabinoids.
All samples screened with FPIA-ADx and collected because of drug content and concentration were confirmed with GC-MS. In Table IV , the results obtained with FPIA-ADx, Abusign (cannabinoids 50 ng/mL), and GC-MS confirmation of 11-noro Ag-THC-9-COOH are presented. A sample was considered positive with FPIA-ADx if the result was > 50 ng/mL, with the Abusign drugs test if at least three people observed the test positive at t = 5 rain, and with the confirmation if the concentration of 11-nor-Ag-THC-9-COOH was higher than 15 ng/mL. In comparison with FPIA-ADx, the Abusign test slides had a higher sensitivity but a lower specificity.
Discussion
The objective of the present study was to examine the performance of the Abusign slide tests near the cutoff value in comparison with FPIA-ADx and confirmation with GC-MS. Our results show that there is considerable variability in reading the test between observers as well as for one observer over time. In addition, we showed that, in comparison with FPIA-ADx, the test slide for cannabinoids has a higher sensitivity but a lower specificity. In daily practice, most problems occur near the cutoff, and most questions arise when concentrations of the drugs of abuse fluctuate around this value. The selection of urine samples was based on this criterion. When the concentration of the drug of abuse is near the cutoff, this study shows that the test result using Abusign can depend on the person by whom the test is being read and on the time at which the test is being read. This has important consequences in daily practice. The Abusign test becomes more reliable when the test is judged by two or more persons. Therefore, it is advisable to use the Abusign slide test only when a strict protocol (i.e., always at the same time after incubation) is possible and when the test is carried out by more than one person with some experience reading the test. The experience is necessary because most of the people reading the results in this evaluation had trouble calling a test positive when no line was observed and calling a test negative when a line appeared. This meant that expertise in performing the Abusign slide tests was necessary to prevent mistakes. In addition, the inconvenient shade cast on the result window because the result window was beneath the slide surface, the poor quality of the reading zone that was sometimes pink and sometimes colorless, and the presence of vertical pink lines in the result window were troublesome for getting a reliable test result.
In comparison with FPIA-ADx, the Abusign cannabinoids (50 ng/mL) slide test had very high sensitivity (87%) but low specificity (51%). A high false-pnsitive rate is unacceptable in daily practice because it necessitates costly confirmation for many samples. Judging on screening alone is unacceptable, given the often serious consequences for the person tested.
Another limitation of slide tests in general is that they only give a result as positive or negative: nothing can be concluded about the amount of drug present in the urine. This means that the result cannot be interpreted in relation to earlier tests for the same individual, which is in contrast to irnmunoassays such as FPIA and EMIT. For these tests, the result is generated by the instrument and cannot be influenced by the operator. The analyses are carried out on instruments that can be automated and coupled to computer systems. This is a great advantage when large numbers of samples are to be analyzed. A disadvantage of these methods is that the instruments are expensive.
Conclusion
It may be concluded from our study that the Abusign test slides cannot be advised for screening for drugs of abuse in prisons or detoxification centers where a reliable test result is needed. The test result depends too much on the observer and time. In addition, the specificity is too low. The test may be of value for usage in emergency toxicology when a quick result is needed and when an answer to the question of whether large quantities of a drug of abuse are present or absent is the sole prerequisite.
